Prosecution Insights
Last updated: April 19, 2026
Application No. 18/660,726

ALKOXYLATED (HYDROXYALKYL)AMINOPHENOL POLYMERS AND METHODS OF USE

Non-Final OA §DP
Filed
May 10, 2024
Examiner
FANG, SHANE
Art Unit
1766
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Ecolab Usa Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
95%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
1136 granted / 1491 resolved
+11.2% vs TC avg
Strong +19% interview lift
Without
With
+19.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
51 currently pending
Career history
1542
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
16.5%
-23.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1491 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status as Continuation This application discloses and claims only subject matter disclosed in prior US 12018130, effectively filed 10/21/20, and names the inventor or at least one joint inventor named in the prior application. Accordingly, this application may constitute a continuation or division. Should applicant desire to claim the benefit of the filing date of the prior application, attention is directed to 35 U.S.C. 120 and 37 CFR 1.78. Objections The abstract is objected to because of the following informalities: it should not include phrases that can be implied, such as “disclosed”. Appropriate correction is required. According to the Manual of Patent Examining Procedure (MPEP) 608.01(b), when writing an abstract of a patent disclosure, the language should be clear and concise, and avoid phrases that can be implied. These phrases include: "The disclosure concerns, "The disclosure defined by this invention, and "The disclosure describes. The abstract should also avoid legal phraseology and forms often used in patent claims, such as "means" and "said". The abstract's purpose is to provide technical information and help readers decide if they need to read the full patent text. The abstract should be as concise as possible, but should still be able to describe the disclosure sufficiently. In English, the abstract should be around 50 to 150 words, but the PCT range is not absolute. Publication problems may occur if the PCT limit is exceeded. Claim Rejections - Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claim(s) 1-2, 4-5, and 12-15 is (are) rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 16-21 of US 11767393. ‘393 (claims 16-21) meets instant claims 1-2, 4-5, and 12-15, because it discloses the claimed industrial process of treating crude oil (stream) by adding a solvent based composition comprising 0.1-10k ppm of the claimed polymer of claim 1: PNG media_image1.png 574 288 media_image1.png Greyscale PNG media_image2.png 303 628 media_image2.png Greyscale The process stream comprises wax, and the polymer composition further comprise solvent such as ethylene glycol and an additive such as corrosion inhibitor. Allowable Subject Matter The following is an examiner's statement of reasons for allowance: Claim(s) 1-17 is(are) allowable over the closest prior art: Holtrup et al. (US 20020156136) listed on IDS in proviso the above ODP issue is resolved. Claim(s) 3, 6-11, and 16-17 is(are) objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. As to claim 1, Holtrup (abs., claims, examples) discloses: PNG media_image3.png 478 294 media_image3.png Greyscale PNG media_image4.png 279 295 media_image4.png Greyscale and an example of producing amino phenol aldehyde resin: PNG media_image5.png 477 416 media_image5.png Greyscale However, Holtrup fails to disclose the polymer having hydroxylalkoxy pendant group on the amino group of claim 1. Therefore, claim 1 is(are) provisionally allowable together with its dependent claims 2-17. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance”. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHANE FANG whose telephone number is (571)270-7378. The examiner can normally be reached on Mon-Thurs. 8am-6pm. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Randy Gulakowski can be reached on 571.572.1302. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHANE FANG/Primary Examiner, Art Unit 1766
Read full office action

Prosecution Timeline

May 10, 2024
Application Filed
Mar 03, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600818
PROCESS FOR THE PREPARATION OF STERICALLY HINDERED NITROXYL ETHERS
2y 5m to grant Granted Apr 14, 2026
Patent 12595395
KIT-OF-PARTS FOR CURABLE POLYASPARTIC ACID ESTER-BASED COATING COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595338
PROCESS FOR PREPARING A HYDROXY GROUP FUNCTIONALIZED THIOETHER
2y 5m to grant Granted Apr 07, 2026
Patent 12577411
GAS-BARRIER COATING COMPOSITION AND GAS-BARRIER LAMINATE
2y 5m to grant Granted Mar 17, 2026
Patent 12581846
ELECTROLUMINESCENT POLYMER BASED ON PHENANTHROIMIDAZOLE UNITS, PREPARATION METHOD THEREFOR, AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
95%
With Interview (+19.0%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1491 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month